微管蛋白抑制剂在前列腺癌中的应用进展

打开文本图片集

中图分类号R979.1；R737.25 文献标志码A 文章编号 1001-0408（2025）13-1683-06

DOI 10.6039/j.issn.1001-0408.2025.13.22

Progress in the application of microtubulin inhibitors in prostate cancer

GUO Nan，DOU Baokai，ZHANG Jing（Dept.of Pharmacy，Provincial Hospital Afiliated to Shandong Firs MedicalUniversity，Jinan ，China）

ABSTRCTWhenprostatecancer（PCa）progreses tothemetastaticcastration-resistantstage，significantchalengesarisein clinicaltreatment.Microtubulinibitorshavebcomefis-liedugsforthetreamentofmetastaticastratio-resistantPCaduto their uniqe mechanismofaction.Among them，taxanes （.g.docetaxeland cabazitaxel）remainstandardcare with proven survival benefits，whileothermicrotubuleinhbitors（e.g.vincristine，colchicine）showlimitedclinicalutiltyduetotoxicity.Curently，the clinicalappoachprimarilyemploysdocetaxel-basedtripletherapyandcombinedwithimmunecheckpointinhbitorstoimprovethe prognosisofPCapatients，reversetheimmunosuppresive stateof the tumor microenvironment，and enhance therapeutic eicacy. DespitetheremarkableclinicaleffcacyofmicrotubuleinhibitorsinthetreatmentofPCa，theemergenceofdrugresistancehas limitedtheirlong-termaplication.Toaddressthisisue，researchershaveexplorednewsolutions，includingthedevelopmentof novelmicrotubuleiibitorsincombinationwithATP-bindingcasetesufamilyBmemberlihibitors，theconcuentuseoffatty acidsynthaseinhibitorswithmicrotubuleinhibitors，andthedevelopmentofdegradersbasedonproteolysis-targetingchimeras technology.Futureresearchshouldfocusontargetdiscovery，drugformulationoptimization，andpersonalizedapproachesto overcome current therapeutic limitations.

KEYWORDSprostatecancer；metastaticcastration-resistantprostatecancer;microtubuleinhibitors；docetaxel；combination therapy；drug resistance

前列腺癌（prostatecancer，PCa）是男性常见的恶性肿瘤，其发病率在美国癌症中居首位[1，在我国的发病率也逐渐上升2。（剩余16104字）